Ann: PARADIGM RECEIVES FEEDBACK FROM US FDA ON IND SUBMISSION, page-253

Agree that it is good to get some clarity on revised timetables, specially when there are significant delays.

Agree also with Dogman, Bio plays (specially early ones and pre-revenue) are notoriously long plays and volatile at the best of times.

Look how long it took to get RRV and CHIK-V peer review , I remember a few posters on here commenting that they were worried about the whole RRV program as we hadn't had an update for so long...OA 2B I'm sure isn't too far away but I too have heard it has been exceptionally delayed due to peer reviewers having their work cut out for them due to all the Covid studies.